CA2094341A1 - Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker - Google Patents

Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker

Info

Publication number
CA2094341A1
CA2094341A1 CA002094341A CA2094341A CA2094341A1 CA 2094341 A1 CA2094341 A1 CA 2094341A1 CA 002094341 A CA002094341 A CA 002094341A CA 2094341 A CA2094341 A CA 2094341A CA 2094341 A1 CA2094341 A1 CA 2094341A1
Authority
CA
Canada
Prior art keywords
spermine
spermidine
acetyltransferase
assay
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002094341A
Other languages
English (en)
French (fr)
Inventor
Carl W. Porter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2094341A1 publication Critical patent/CA2094341A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002094341A 1992-04-28 1993-04-19 Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker Abandoned CA2094341A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87509192A 1992-04-28 1992-04-28
US875,091 1992-04-28

Publications (1)

Publication Number Publication Date
CA2094341A1 true CA2094341A1 (en) 1993-10-29

Family

ID=25365191

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002094341A Abandoned CA2094341A1 (en) 1992-04-28 1993-04-19 Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker

Country Status (4)

Country Link
US (1) US5498522A (enExample)
EP (1) EP0568338A2 (enExample)
JP (1) JPH0662896A (enExample)
CA (1) CA2094341A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US5650096A (en) * 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
EP0824345A4 (en) * 1995-04-25 1999-08-25 Oridigm Corp REGULATION OF METABOLIC S-ADENOSYL METHIONINE AND APPLICATION TO DIAGNOSIS AND THERAPY
CA2264745C (en) * 1996-09-13 2003-11-11 University Of Florida Research Foundation, Inc. Method of inhibiting biosynthesis of eif5a
US8198334B2 (en) * 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
AU2003231670B2 (en) * 1997-10-27 2006-06-08 Slil Biomedical Corporation Methods for modulating macrophage proliferation using polyamine analogs
US7087648B1 (en) * 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
JP3709078B2 (ja) * 1998-08-27 2005-10-19 ヤマサ醤油株式会社 ジアセチルポリアミンの測定法及びキット
EP1129064B1 (en) 1998-11-12 2008-01-09 Invitrogen Corporation Transfection reagents
AU778343B2 (en) * 1999-02-05 2004-12-02 Mediquest Therapeutics, Inc. Antizyme modulators and their use
AU4679900A (en) * 1999-04-30 2000-11-17 Slil Biomedical Corporation Conformationally restricted polyamine analogs as disease therapies
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
JP2002543163A (ja) * 1999-04-30 2002-12-17 スリル バイオメディカル コーポレイション 癌および前立腺疾患のための治療としての結合体
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
MXPA02006843A (es) * 2000-01-12 2004-04-05 Ventana Med Syst Inc Metodo para cuantificar una proteina por analisis de imagenes.
AU2001297817A1 (en) * 2000-11-08 2002-11-25 Eli Lilly And Company Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
US7030126B2 (en) * 2001-11-16 2006-04-18 Als Therapy Development Foundation, Inc. Use of polyamine analogs for amyotrophic lateral sclerosis
AU2002364539A1 (en) 2001-12-07 2003-06-23 Cellgate, Inc. Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
JP2004189714A (ja) * 2002-12-09 2004-07-08 Rasanen Tiina-Liisa すい臓炎の治療と予防ならびに肝臓再生機能の誘導のための薬剤
CN102344950B (zh) * 2011-05-31 2015-08-26 上海拜瑞曼克生物科技有限公司 一种用于检测ssat底物的乙酰化代谢物的方法
US9585380B2 (en) 2011-09-02 2017-03-07 Temple University—Of the Commonwealth System of Higher Education SSAT mRNA translation repression and activation
WO2014117272A1 (en) * 2013-01-30 2014-08-07 Biomark Technologies Inc. Spermidine/spermine n1-acetyltransferase antibodies as anti-cancer drug compounds
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells

Also Published As

Publication number Publication date
US5498522A (en) 1996-03-12
EP0568338A2 (en) 1993-11-03
JPH0662896A (ja) 1994-03-08
EP0568338A3 (enExample) 1994-03-30

Similar Documents

Publication Publication Date Title
CA2094341A1 (en) Methods for the use of spermidine/spermine n1-acetyltransferase as a prognostic indicator and/or tumor response marker
Kawasaki et al. Benzene-extracted components are important for the major activity of diesel exhaust particles: effect on interleukin-8 gene expression in human bronchial epithelial cells
Washtien Increased levels of thymidylate synthetase in cells exposed to 5-fluorouracil.
Austin et al. Characterization of the factor in L‐cell conditioned medium capable of stimulating colony formation by mouse marrow cells in culture
Chmura et al. Protein kinase C inhibition induces apoptosis and ceramide production through activation of a neutral sphingomyelinase
Boothman et al. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation
Milano et al. Dihydropyrimidine dehydrogenase activity in cancer patients
Plappert et al. Changes in the repair capacity of blood cells as a biomarker for chronic low‐dose exposure to ionizing radiation
Schuetz et al. Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate-resistant murine L1210 leukemia cell line.
Martinez et al. Nonspecific suppressor cell function in atopic subjects
Goldstein et al. Cystathionine synthase activity in human lymphocytes: induction by phytohemagglutinin
Maziere et al. In situ degradation of sphingomyelin by cultured normal fibroblasts and fibroblasts from patients with Niemann-Pick disease type A and C
Ying et al. Enhanced expression of group II phospholipase A2 in human hepatocellular carcinoma
Luzina et al. PKCα mediates CCL18-stimulated collagen production in pulmonary fibroblasts
EP0925505B1 (en) Detection of cellular exposure to ethanol
WO1986005205A1 (en) Method for the early diagnosis of bordetella diseases and kit therefor
Smeets et al. Differential repair of radiation-induced DNA damage in cells of human squamous cell carcinoma and the effect of caffeine and cysteamine on induction and repair of DNA double-strand breaks
Ayala-Torres et al. Oxysterol sensitive and resistant lymphoid cells: correlation with regulation of cellular nucleic acid binding protein mRNA
Horton et al. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard
Dwyer et al. Transient cholinergic glycoconjugate secretion from swine tracheal submucosal gland cells
Gamcsik et al. Noninvasive detection of elevated glutathione levels in MCF-7 cells resistant to 4-hydroperoxycyclophosphamide
Khandelwal et al. Histamine and some of its metabolites in human body fluids
Schwab et al. Localization of azithromycin in Toxoplasma gondii-infected cells
Pirmohamed et al. Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy.
Brodie et al. Effects of ethanol on voltage-sensitive Na-channels in cultured skeletal muscle: up-regulation as a result of chronic treatment.

Legal Events

Date Code Title Description
FZDE Discontinued